Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +62

Eli Lilly (LLY) Stock Forecast & Price Target (2026)

Analyst upgrade AI-generated analysis

πŸ“ˆ LLY trades at $1,251.61 with a market cap of $1.12T and an RSI of 68 indicating bullish momentum.

🎯 Wall Street consensus price target is $1,385.00 across 30 analysts, suggesting ~10.7% upside potential.

πŸ’° Company beat EPS estimates in 6 of the last 7 quarters, with the latest report exceeding expectations by 27.36%.

πŸ“Š Technical indicators show the stock trading above its 50-day moving average ($1,179.04) and 200-day moving average ($1,079.02).

πŸ‘ Analyst sentiment is strong with 25 out of 30 analysts rating LLY as a Buy or Strong Buy.

πŸ“‰ Insider selling is dominated by Lilly Endowment, Inc. (99% of sales), which the article notes is due to corporate restructuring.

πŸ“ˆ Long-term performance is robust, with a $10k investment from October 2016 growing to ~$186k today including dividends.

πŸ“‰ Open-market insider activity shows net selling over the last 18 months ($3.9B sold vs $4.5M bought).

πŸ“… Historical data indicates June is the strongest month (+7.12% avg) while September is historically weakest (-0.77% avg).

Bullish Signals
  • Eli Lilly trades above key moving averages with an RSI of 68, signaling bullish momentum without being overbought.
  • The company has a strong track record of beating analyst EPS estimates in 6 of its last 7 quarters.
  • The most recent earnings report on August 5, 2026, came in 27.36% above the consensus estimate.
  • Wall Street consensus price target of $1,385.00 implies a potential upside of 10.7% from current levels.
  • Overwhelming analyst support with 25 out of 30 analysts rating the stock as Buy or Strong Buy.
Risk Factors
  • Lilly Endowment, Inc. has been reducing its stake, accounting for 99% of total insider selling activity.
  • Over the last 18 months, insiders reported $3.9 billion in open-market sales versus only $4.5 million in purchases.
Full Analysis
As of October 16, 2026, Eli Lilly and Company (LLY) trades at $1,251.61 with a market capitalization of $1.12 trillion. The stock exhibits bullish technical momentum, trading above its 50-day simple moving average of $1,179.04 and showing an RSI of 68, which indicates strength without being overbought. Wall Street analysts maintain a consensus price target of $1,385.00, representing a potential upside of approximately 10.7% from current levels. Eli Lilly has demonstrated a strong track record of beating earnings estimates, having exceeded analyst EPS expectations in six of its last seven reported quarters. The most recent report on August 5, 2026, saw actual EPS come in 27.36% above the consensus estimate, driving the stock up 1.89% in the first trading session. Analyst sentiment remains overwhelmingly positive, with 25 out of 30 analysts rating the stock as a Buy or Strong Buy. Insider activity shows mixed signals but is largely attributed to corporate restructuring rather than management confidence issues. Lilly Endowment, Inc., which accounts for 99% of total insider selling, has been reducing its stake, while open-market sales by other insiders totaled $3.9 billion over the last 18 months compared to only $4.5 million in purchases. Long-term performance data highlights a decade-long growth trajectory where a $10,000 investment in October 2016 would be worth approximately $186,239 today with dividends reinvested.